Bonfils S, Chen W W, Vatier J
Hepato-Gastroenterology Unit, Hôpital Bichat, Paris, France.
Scand J Gastroenterol Suppl. 1988;146:135-41. doi: 10.3109/00365528809099139.
In 10 healthy male volunteers a dose-response study was carried out with roxatidine acetate, 75, 150, 300, and 600 mg, and placebo on food-stimulated gastric acid secretion (intragastric titration (IGT]. The design of the study, with drug intake 150 min before starting IGT, enabled stable inhibition over the 90-min observation period of the test. Cumulative secretory results showed a dose-related acid secretion inhibition (67% for 75 mg; 87.6% for 150 mg; 98.8% for 300 mg; 99.6% for 600 mg). The results were statistically significantly different from placebo and from each other, except for 300 mg versus 600 mg. With a Lineweaver-Burk plot, the ED50 was 41 mg and r = 0.98. Peak concentrations of roxatidine were observed either at T 150 or T 180. Significant correlation (r = 0.7; p less than 0.001) was obtained for the percentage inhibition with 75 mg and 150 mg together versus peak concentrations. Antisecretory potency with the IGT model applied to normal subjects appears to be of the same order for roxatidine acetate and for ranitidine.
在10名健康男性志愿者中,进行了一项剂量反应研究,使用75毫克、150毫克、300毫克和600毫克的醋酸罗沙替丁以及安慰剂,对食物刺激的胃酸分泌进行研究(采用胃内滴定法(IGT))。该研究的设计是在开始IGT前150分钟服药,从而在90分钟的测试观察期内实现稳定的抑制作用。累积分泌结果显示出与剂量相关的胃酸分泌抑制作用(75毫克时为67%;150毫克时为87.6%;300毫克时为98.8%;600毫克时为99.6%)。除了300毫克与600毫克之间外,这些结果与安慰剂相比以及相互之间在统计学上均有显著差异。通过Lineweaver-Burk图,半数有效剂量(ED50)为41毫克,相关系数r = 0.98。罗沙替丁的峰值浓度在T 150或T 180时观察到。75毫克和150毫克合用时的抑制百分比与峰值浓度之间存在显著相关性(r = 0.7;p小于0.001)。应用于正常受试者的IGT模型显示,醋酸罗沙替丁和雷尼替丁的抗分泌效力似乎处于同一水平。